Amundi Purchases 535,273 Shares of Moderna, Inc. (NASDAQ:MRNA)

Amundi lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 79.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,206,273 shares of the company’s stock after purchasing an additional 535,273 shares during the quarter. Amundi owned 0.31% of Moderna worth $52,075,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Banco Santander S.A. bought a new stake in Moderna in the third quarter worth $3,550,000. John G Ullman & Associates Inc. increased its holdings in shares of Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after buying an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after acquiring an additional 167,596 shares during the last quarter. abrdn plc boosted its holdings in Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares during the period. Finally, Y Intercept Hong Kong Ltd grew its position in Moderna by 30.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock worth $6,760,000 after acquiring an additional 23,881 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Wolfe Research assumed coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Morgan Stanley cut their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $60.63.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $35.01 on Thursday. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The firm has a 50-day moving average of $36.25 and a 200 day moving average of $48.01. The stock has a market cap of $13.51 billion, a P/E ratio of -3.77 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.